Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.17B | 1.09B | 786.91M | 500.62M | 344.86M | Gross Profit |
253.36M | 238.80M | 167.32M | 112.14M | 70.06M | EBIT |
67.45M | 62.18M | 23.34M | 32.34M | 8.35M | EBITDA |
67.45M | 64.47M | 24.94M | 33.64M | 10.25M | Net Income Common Stockholders |
54.34M | 62.04M | 30.36M | 65.77M | 46.46M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
227.95M | 371.09M | 189.30M | 119.42M | 109.30M | Total Assets |
607.10M | 756.62M | 542.99M | 358.06M | 253.93M | Total Debt |
19.27M | 19.39M | 7.71M | 7.42M | 8.32M | Net Debt |
-143.04M | -77.91M | -112.36M | -83.99M | -61.99M | Total Liabilities |
185.04M | 203.19M | 166.02M | 106.24M | 86.98M | Stockholders Equity |
422.06M | 553.43M | 376.97M | 251.82M | 166.95M |
Cash Flow | Free Cash Flow | |||
173.70M | 185.17M | 77.15M | 23.91M | 35.17M | Operating Cash Flow |
179.10M | 188.81M | 80.39M | 26.04M | 36.20M | Investing Cash Flow |
195.79M | -200.53M | -43.87M | 8.77M | -40.03M | Financing Cash Flow |
-309.88M | -11.07M | -7.86M | -13.70M | -6.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $1.88B | 37.59 | 10.11% | ― | 9.47% | -7.81% | |
76 Outperform | $1.88B | 40.04 | 6.05% | 3.64% | -17.69% | -10.24% | |
62 Neutral | $1.41B | 53.97 | 4.43% | ― | 4.35% | ― | |
58 Neutral | $1.48B | ― | -15.97% | ― | 16.29% | 66.01% | |
56 Neutral | $1.59B | ― | -43.33% | ― | 22.29% | -32.89% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
48 Neutral | $1.24B | ― | -54.49% | ― | -2.54% | -322.03% |
On May 22, 2025, Progyny, Inc. held its Annual Meeting of Stockholders where key decisions were made regarding the company’s governance and financial oversight. Stockholders elected Class III directors, ratified Ernst & Young LLP as the independent accounting firm, but did not approve the executive compensation package, indicating potential concerns among stakeholders about executive pay.
The most recent analyst rating on (PGNY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
On April 9, 2025, Dr. Fred E. Cohen informed Progyny, Inc. that he will not seek reelection at the company’s 2025 Annual Meeting of Stockholders. His decision is not due to any disagreement with the company’s operations, policies, or practices, and he will remain a director until the end of his current term.